[
  {
    "ts": null,
    "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q3 2025 Update",
    "summary": "Discover Yacktman Asset Management's Q3 2025 portfolio moves, key holdings, and strategy insights.",
    "url": "https://finnhub.io/api/news?id=467305fe3a0b54094e9177db03d8a88282e46b4bb97a7db017c7b02e4954ee6a",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762295674,
      "headline": "Tracking AMG's Yacktman Asset Management Portfolio - Q3 2025 Update",
      "id": 137332134,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/186805810/image_186805810.jpg?io=getty-c-w1536",
      "related": "JNJ",
      "source": "SeekingAlpha",
      "summary": "Discover Yacktman Asset Management's Q3 2025 portfolio moves, key holdings, and strategy insights.",
      "url": "https://finnhub.io/api/news?id=467305fe3a0b54094e9177db03d8a88282e46b4bb97a7db017c7b02e4954ee6a"
    }
  },
  {
    "ts": null,
    "headline": "Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn",
    "summary": "Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.",
    "url": "https://finnhub.io/api/news?id=6a427fe6f1bbae9c039b82ff7cc049806d9eefb495e6931aee06c7338819e747",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762259116,
      "headline": "Kimberly-Clark buys troubled Tylenol-maker Kenvue for $48.7bn",
      "id": 137312063,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Kenvue is under the microscope from the Trump administration, though Kimberly-Clark sees a $32bn horizon.",
      "url": "https://finnhub.io/api/news?id=6a427fe6f1bbae9c039b82ff7cc049806d9eefb495e6931aee06c7338819e747"
    }
  },
  {
    "ts": null,
    "headline": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
    "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
    "url": "https://finnhub.io/api/news?id=771db1e5630e8730bfc08d36ccd650512c1dd6ea7e1e533f3452b69b0affd8a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762258140,
      "headline": "$144.85 Bn Disposable Medical Device Markets, 2025-2030: Opportunities in Innovation in Sustainable Materials, and Expansion in Emerging Markets and Underserved Regions",
      "id": 137312064,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The global disposable medical device market is set to expand from USD 113.95 billion in 2025 to USD 144.85 billion by 2030, driven by a 4.9% CAGR. Factors such as heightened concern over hospital-acquired infections (HAIs), increased surgical procedures, and demand for cost-effective, single-use solutions propel growth. The drug delivery devices segment is leading in growth due to rising chronic disease cases and vaccine programs. The plastic-based segment is growing due to cost-effectiveness an",
      "url": "https://finnhub.io/api/news?id=771db1e5630e8730bfc08d36ccd650512c1dd6ea7e1e533f3452b69b0affd8a4"
    }
  },
  {
    "ts": null,
    "headline": "Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal",
    "summary": "Combined company aims to become global health leader by 2026.",
    "url": "https://finnhub.io/api/news?id=926e03daf8a855a158bccee9c92e660ae7807565cea656ab23b7f7ddd2a137f9",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762254850,
      "headline": "Kimberly-Clark To Acquire Kenvue In $48.7 Billion Mega Deal",
      "id": 137312065,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "Combined company aims to become global health leader by 2026.",
      "url": "https://finnhub.io/api/news?id=926e03daf8a855a158bccee9c92e660ae7807565cea656ab23b7f7ddd2a137f9"
    }
  },
  {
    "ts": null,
    "headline": "Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?",
    "summary": "In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...",
    "url": "https://finnhub.io/api/news?id=db076e8bc8fff75b98dff6f027ba5fc0133beb715a953b5a263b605699197cd8",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762251555,
      "headline": "Will Pipeline Milestones and New Oral Therapies Shift Johnson & Johnson's (JNJ) Growth Narrative?",
      "id": 137312066,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "In the past week, Johnson & Johnson unveiled a series of positive clinical updates and regulatory milestones for key pipeline candidates, including icotrokinra and nipocalimab, across multiple immunology and dermatology indications. The announcements featured favorable long-term efficacy and safety data, new head-to-head trials, and expanded FDA designations, indicating pipeline strength and broadening commercial opportunities. One key insight is the mounting preference among patients and...",
      "url": "https://finnhub.io/api/news?id=db076e8bc8fff75b98dff6f027ba5fc0133beb715a953b5a263b605699197cd8"
    }
  },
  {
    "ts": null,
    "headline": "Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use",
    "summary": "PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.",
    "url": "https://finnhub.io/api/news?id=81ae1c03682ca13fad4dd824dda4827b8f91514b13d94fad5da75bafaffff27f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762239600,
      "headline": "Tulyp Medical Emerges From Sofinnova’s Medtech Accelerator and Announces FDA Submission Following Initial First-in-Human Use",
      "id": 137312068,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "PARIS, November 04, 2025--Tulyp Medical, a Paris-based startup developing a medical device for intelligent pressure-driven perfusion, emerged from stealth and announced it has submitted its 510(k) application to the U.S. Food and Drug Administration (FDA). The company’s debut follows positive results from its initial first-in-human study.",
      "url": "https://finnhub.io/api/news?id=81ae1c03682ca13fad4dd824dda4827b8f91514b13d94fad5da75bafaffff27f"
    }
  },
  {
    "ts": null,
    "headline": "Alvotech faces FDA setback for its Simponi biosimilar AVT05",
    "summary": "The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.",
    "url": "https://finnhub.io/api/news?id=292938801a743e8e26417ffa714053f60c9de3156adb666e71c17968e3f34ddf",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1762239600,
      "headline": "Alvotech faces FDA setback for its Simponi biosimilar AVT05",
      "id": 137312067,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "JNJ",
      "source": "Yahoo",
      "summary": "The proposed biosimilar to J&J’s Simponi was rejected by the FDA due to manufacturing concerns.",
      "url": "https://finnhub.io/api/news?id=292938801a743e8e26417ffa714053f60c9de3156adb666e71c17968e3f34ddf"
    }
  }
]